{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\", docket_id = \"FDA-1977-N-0025\" and posted_year = 2018 sorted by posted_date descending", "rows": [["FDA-1977-N-0025-0231", "FDA", "FDA-1977-N-0025", "Tentative Final Monographs: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Use; Partial Withdrawal", "Proposed Rule", "Withdrawal", "2018-05-14T04:00:00Z", 2018, 5, "2018-05-14T04:00:00Z", null, "2018-05-14T20:35:15Z", "2018-10194", 0, 0, "0900006483262e32"], ["FDA-1977-N-0025-0053", "FDA", "FDA-1977-N-0025", "Reference 45: Bergmann, J. F. et al., \"Endoscopic Evaluation of the Effect of Ketoprofen, Ibuprofen, and Aspirin on the Gastroduodenal Mucosa,\" European Journal of Clinical Pharmacology, 42:685, 1992 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T13:05:42Z", null, 0, 0, "09000064805da241"], ["FDA-1977-N-0025-0048", "FDA", "FDA-1977-N-0025", "Reference 56: Mclntire, S. C. et al, \"Acute Flank Pain and Reversible Renal Dysfunction Associated with Nonsteroidal Anti-inflammatory Drug Use,\" Pediatrics, 92:459-460, 1993 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T13:36:13Z", null, 0, 0, "09000064805da234"], ["FDA-1977-N-0025-0193", "FDA", "FDA-1977-N-0025", "Table of Contents re: Comment from Wyeth Consumer Healthcare", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-04-05T19:45:44Z", null, 0, 0, "09000064805da2ca"], ["FDA-1977-N-0025-0185", "FDA", "FDA-1977-N-0025", "Appendix II re: Monograph Response re: Comment from Wyeth Consumer Healthcare", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-04-05T20:13:23Z", null, 0, 0, "09000064805da2d2"], ["FDA-1977-N-0025-0230", "FDA", "FDA-1977-N-0025", "Tab 5. Reference List re: Comment from McNeil Consumer & Specialty Pharmaceuticals", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-21T13:12:43Z", null, 0, 0, "09000064805da2e1"], ["FDA-1977-N-0025-0146", "FDA", "FDA-1977-N-0025", "Background Material-Reference 9", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2018-01-02T19:17:49Z", null, 0, 0, "09000064805da29b"], ["FDA-1977-N-0025-0139", "FDA", "FDA-1977-N-0025", "Reference 36: Gurwitz, J. H. et al., \"The Impact of Ibuprofen on the Efficacy of Antihypertensive Treatment with Hydrochlorthiazide in Elderly Patients,\" Journal of Gerontology. 51A: M74- M79, 1996 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T14:14:57Z", null, 0, 0, "09000064805da2a2"], ["FDA-1977-N-0025-0101", "FDA", "FDA-1977-N-0025", "Reference 116: Bharija, S. C., and M. S. Belhaj, \"Fixed Drug Eruption on Three Independent Sites Induced by Three Chemically Unrelated Drugs,\" Dermatologica, 181:237, 1990 (letters) re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T17:41:43Z", null, 0, 0, "09000064805da272"], ["FDA-1977-N-0025-0166", "FDA", "FDA-1977-N-0025", "Reference 22: Adams, S. S., and J. Warwick-Buckler, \"Ibuprofen and Flurbiprofen,\" Clinics in Rheumatic Diseases. 5:359-379, 1979 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T13:40:18Z", null, 0, 0, "09000064805da2b1"], ["FDA-1977-N-0025-0133", "FDA", "FDA-1977-N-0025", "Reference 43: Kaufman, D. W. et al., \"Nonsteroidal Anti-inflammatory Drug Use in Relation to Major Upper Gastrointestinal Bleeding,\" Clinical Pharmacology and Therapeutics. 53:485-494, 1993 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T14:48:58Z", null, 0, 0, "09000064805da2a8"], ["FDA-1977-N-0025-0040", "FDA", "FDA-1977-N-0025", "Reference 62: Spierto, T. J., M. B. Kaufman, and C. A. Stoukedes., \"Acute Renal Failure Associated with the Use of Over-the-Counter Ibuprofen,\" The Annals of Pharmacotherapy, 26:714,1992 (letter) re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T13:48:22Z", null, 0, 0, "09000064805da23c"], ["FDA-1977-N-0025-0179", "FDA", "FDA-1977-N-0025", "Request for Extension from Albemarle Corporation", "Other", "Request for Extension", "2018-01-02T05:00:00Z", 2018, 1, "2018-01-02T05:00:00Z", "2002-11-20T04:59:59Z", "2019-01-30T23:54:29Z", null, 0, 0, "09000064805da2d8"], ["FDA-1977-N-0025-0038", "FDA", "FDA-1977-N-0025", "Reference 74: Deutsch P. H., and G. L. Mandell, \"Reversible Pelger-Huet Anomaly Associated with Ibuprofen Therapy,\" Archives of Internal Medicine, 145:166, 1985 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:20:54Z", null, 0, 0, "09000064805da22f"], ["FDA-1977-N-0025-0016", "FDA", "FDA-1977-N-0025", "Reference 85: Butterfield J. H. et al., \"Severe Generalized Reactions to Ibuprofen: Report of a Case,\" Journal of Rheumatology, 13:649-650, 1986 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:45:58Z", null, 0, 0, "09000064805da21c"], ["FDA-1977-N-0025-0071", "FDA", "FDA-1977-N-0025", "Reference 105: Bouland, D. L., N. L. Specht, and D. R. Hegstad, \"Ibuprofen and Aseptic Meningitis,\" Annals of Internal Medicine, 104:731, 1986 (letter) re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T15:51:31Z", null, 0, 0, "09000064805da267"], ["FDA-1977-N-0025-0111", "FDA", "FDA-1977-N-0025", "Reference 106: Davis, B. J. et al., \"Drug-Induced Aseptic Meningitis Caused by Two Medications,\" Neurology, 44:984-985,1994 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T15:53:21Z", null, 0, 0, "09000064805da268"], ["FDA-1977-N-0025-0105", "FDA", "FDA-1977-N-0025", "Reference 112: Eustace, S., and B. Buff, \"Magnetic Resonance Imaging in Drug-Induced Meningitis,\" Canadian Association of Radiologists Journal, 45:463-465, 1994 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T17:30:17Z", null, 0, 0, "09000064805da26e"], ["FDA-1977-N-0025-0219", "FDA", "FDA-1977-N-0025", "Tab 10 re: Comment from Albemarle Corporation", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-22T14:51:33Z", null, 0, 0, "09000064805da2f2"], ["FDA-1977-N-0025-0100", "FDA", "FDA-1977-N-0025", "Reference 117: Khan, A. R., \"Erythema Nodosum After Ibuprofen,\" British Medical Journal, 288:1048,1984 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T17:44:15Z", null, 0, 0, "09000064805da273"], ["FDA-1977-N-0025-0023", "FDA", "FDA-1977-N-0025", "Reference 92: Ewert, B. H., \"Ibuprofen-Associated Meningitis in a Woman with Only Serologic Evidence of a Rheumatologic Disorder,\" The American Journal of Medical Sciences, 287:326-327, 1989 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T15:12:25Z", null, 0, 0, "09000064805da223"], ["FDA-1977-N-0025-0018", "FDA", "FDA-1977-N-0025", "Reference 87: Ekert, F. et al, \"Anaphylactoid Reactions Due to Ibuprofen\" (abstract), Journal of Allergy and Clinical Immunology, 89:347, 1992 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:50:23Z", null, 0, 0, "09000064805da21e"], ["FDA-1977-N-0025-0034", "FDA", "FDA-1977-N-0025", "Reference 76: Mathur, S. L., \"Ibuprofen in Bronchial Asthma,\" Journal of the Association of Physicians of India, 36:523, 1988 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:25:44Z", null, 0, 0, "09000064805da231"], ["FDA-1977-N-0025-0092", "FDA", "FDA-1977-N-0025", "Reference 125: Kaplan, B. H. et al., \"Aseptic Meningitis and Iridocyclitis Related to Ibuprofen,\" American Journal of Ophthalmology, 117:119-120, 1994 (letters) re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T18:07:43Z", null, 0, 0, "09000064805da27d"], ["FDA-1977-N-0025-0126", "FDA", "FDA-1977-N-0025", "Reference 133: Minuz, P. et al., \"Amlodipine and Haemodynamic Effects of Cyclo-Oxygenase Inhibition,\" British Journal of Clinical Pharmacology, 39:45-50, 1995 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T18:28:42Z", null, 0, 0, "09000064805da285"], ["FDA-1977-N-0025-0129", "FDA", "FDA-1977-N-0025", "Reference 130: Minuz, P. et al., \"Antihypertensive Activity of Enalapril. Effect of Ibuprofen and Different Salt Intakes,\" Journal of Clinical Hypertension, 3:645-653, 1987 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T18:26:20Z", null, 0, 0, "09000064805da282"], ["FDA-1977-N-0025-0098", "FDA", "FDA-1977-N-0025", "Reference 119: Shelly, E. D., and W. B. Shelley, \"Ibuprofen Urticaria,\" Journal of the American Academy of Dermatology, 17:1057-1058, 1987 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T17:51:57Z", null, 0, 0, "09000064805da276"], ["FDA-1977-N-0025-0069", "FDA", "FDA-1977-N-0025", "Reference 147: Giles, A. D. et al., \"A Single-Dose Assessment of an Ibuprofen/Codeine Combination in Post-Operative Dental Pain,\" International Journal of Oral Maxillofacillary Surgery, 15:727-732, 1986 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T20:03:55Z", null, 0, 0, "09000064805da251"], ["FDA-1977-N-0025-0087", "FDA", "FDA-1977-N-0025", "Reference 153: Nebe, J., M. Heier, and H. C. Diener, \"Low-dose Ibuprofen in Self-Medication of Mild to Moderate Headache: A Comparison with Acetylsalicylic Acid and Placebo,\" Cephalalgia, 15:531-535,1995 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T20:18:25Z", null, 0, 0, "09000064805da256"], ["FDA-1977-N-0025-0078", "FDA", "FDA-1977-N-0025", "Reference 98: Gilbert, G. J., and H. W. Eichenbaum, \"Ibuprofen-induced Meningitis in an Elderly Patient with Systemic Lupus Erythematosus,\" Southern Medical Journal 82:514-515, 1989 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T15:25:18Z", null, 0, 0, "09000064805da25f"], ["FDA-1977-N-0025-0079", "FDA", "FDA-1977-N-0025", "Reference 97: Thilman, A. F. et al., \"Recurrent Aseptic Meningitis (Mollaret Meningitis)-Spontaneous and Drug-Induced Appearance,\" Fortschritte der Neurologie-Psychiatrie (Stuttgart), 59:493-497, 1991 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T15:22:23Z", null, 0, 0, "09000064805da25e"], ["FDA-1977-N-0025-0073", "FDA", "FDA-1977-N-0025", "Reference 103: Van der Zwan, A., and J. G. Van Dam, \"Side Effects of Medicinal Agents-Ibuprofen Meningitis,\" Nederlands Tijdschrift voor Geneeskunde, 136:1613-1614, 1992 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T15:46:44Z", null, 0, 0, "09000064805da264"], ["FDA-1977-N-0025-0125", "FDA", "FDA-1977-N-0025", "Reference 134: Pancera, P. et al., \"Changes in Peripheral Hemodynamics and Vasodilating Prostaglandins After High-dose Short-term Ibuprofen in Chronically Treated Hypertensive Patients,\" Prostaglandins, Leukotrienes and Essential Fatty Acids, 54:217-222, 1996 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T18:44:45Z", null, 0, 0, "09000064805da286"], ["FDA-1977-N-0025-0117", "FDA", "FDA-1977-N-0025", "Background Material-References to Appendix D", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-01-31T19:16:34Z", null, 0, 0, "09000064805da28e"], ["FDA-1977-N-0025-0203", "FDA", "FDA-1977-N-0025", "Tab 3. Comments on Proposed Rule 67 FR 54139 re: Comment from McNeil Consumer & Specialty Pharmaceuticals", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-21T13:09:29Z", null, 0, 0, "09000064805da2e0"], ["FDA-1977-N-0025-0216", "FDA", "FDA-1977-N-0025", "Tab 1 re: Comment from Albemarle Corporation", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-22T14:12:48Z", null, 0, 0, "09000064805da2ef"], ["FDA-1977-N-0025-0222", "FDA", "FDA-1977-N-0025", "Tab 6 re: Comment from Albemarle Corporation", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-22T14:24:45Z", null, 0, 0, "09000064805da2f5"], ["FDA-1977-N-0025-0109", "FDA", "FDA-1977-N-0025", "Reference 108: Morgan, A., and D. Clark, \"CNS Adverse Effects of Nonsteroidal Anti-inflammatory Drugs,\" CNS Drugs, 4:281-290, 1998 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T17:17:27Z", null, 0, 0, "09000064805da26a"], ["FDA-1977-N-0025-0088", "FDA", "FDA-1977-N-0025", "Reference 152: Schachtel, B. P., S. A. Furey, and W. R. Thoden, \"Nonprescription Ibuprofen and Acetaminophen in the Treatment of Tension-Type Headache,\" Journal of Clinical Pharmacology, 36:1120-1125,1996 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T20:15:38Z", null, 0, 0, "09000064805da255"], ["FDA-1977-N-0025-0103", "FDA", "FDA-1977-N-0025", "Reference 114: Jensen, S. et al., \"Ibuprofen-induced Meningitis in a Male with Systemic Lupus Erythematosus,\" Acta Medica Scandinavica, 221:509-511, 1987 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T17:37:01Z", null, 0, 0, "09000064805da270"], ["FDA-1977-N-0025-0097", "FDA", "FDA-1977-N-0025", "Reference 120: Ben-Chetrit, E., and A. Rubinow, \"Exacerbation of Psoriasis by Ibuprofen,\" Cutis. 38:45, 1986 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T17:54:49Z", null, 0, 0, "09000064805da278"], ["FDA-1977-N-0025-0080", "FDA", "FDA-1977-N-0025", "Reference 96: Perera, D. R., A. K. Seiffert, and H. M. Greeley, \"Ibuprofen and Meningoencephalitis,\" Southern Medical Journal, 100:619, 1984 (letter) re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T15:20:35Z", null, 0, 0, "09000064805da25d"], ["FDA-1977-N-0025-0169", "FDA", "FDA-1977-N-0025", "Reference 19: Jamali, F. et al., \"Human Pharmacokinetics of Ibuprofen Enantiomers Following Different Doses and Formulations: Intestinal Chiral Inversion,\" Journal of Pharmaceutical Sciences. 81:221-225, 1992 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T13:32:48Z", null, 0, 0, "09000064805da2ae"], ["FDA-1977-N-0025-0081", "FDA", "FDA-1977-N-0025", "Reference 159: Gaitonde, B. B., K. Dattani, and K. Morwani, \"Antipyretic Activity of Ibuprofen (Brufen),\" Journal of the re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T19:19:43Z", null, 0, 0, "09000064805da25c"], ["FDA-1977-N-0025-0175", "FDA", "FDA-1977-N-0025", "Reference from FDA", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-11T14:34:46Z", null, 0, 0, "09000064805da2c4"], ["FDA-1977-N-0025-0116", "FDA", "FDA-1977-N-0025", "Background Material-References to Appendix E", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2018-01-02T19:11:56Z", null, 0, 0, "09000064805da28f"], ["FDA-1977-N-0025-0184", "FDA", "FDA-1977-N-0025", "Appendix II re: Monograph Response re: Comment from Wyeth Consumer Healthcare", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-04-05T20:16:29Z", null, 0, 0, "09000064805da2d3"], ["FDA-1977-N-0025-0115", "FDA", "FDA-1977-N-0025", "Background Material-References to Appendix E (Cover Card)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2018-01-02T19:11:56Z", null, 0, 0, "09000064805da290"], ["FDA-1977-N-0025-0062", "FDA", "FDA-1977-N-0025", "Reference 37: Agency Letter to Prescription NSAID Manufacturers/Sponsors, in OTC Vol. 03BTFM (I), Docket No. 77N-094I, Dockets Management Branch re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T14:17:13Z", null, 0, 0, "09000064805da24a"], ["FDA-1977-N-0025-0142", "FDA", "FDA-1977-N-0025", "Reference 33: Rudy, A. C. et al., \"Stereoselective Metabolism of Ibuprofen in Humans: Administration of R-, S- and Racemic ibuprofen,\" Journal of Pharmacology and Experimental Therapeutics. 259:1133-1139,1991 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T14:07:16Z", null, 0, 0, "09000064805da29f"], ["FDA-1977-N-0025-0158", "FDA", "FDA-1977-N-0025", "Reference 30: Leeman, T. D. et al, \"A Major Role for Cytochrome P450TB (CYP23 Subfamily) in the Actions of Non-Steroidal Anti-inflammatory Drugs,\" Drugs Under Experimental and Clinical Research. 19:189-195,1993 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T14:01:13Z", null, 0, 0, "09000064805da2b9"], ["FDA-1977-N-0025-0135", "FDA", "FDA-1977-N-0025", "Reference 41: Griffin, M. R. et al., \"Nonsteroidal Anti-inflammatory Drug Use and Increased Risk for Peptic Ulcer Disease in Elderly Persons,\" Annals of Internal Medicine. 114:257-263, 1991 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T14:36:08Z", null, 0, 0, "09000064805da2a6"], ["FDA-1977-N-0025-0044", "FDA", "FDA-1977-N-0025", "Reference 58: Moss, A. H. et al., \"Over-the-Counter Ibuprofen and Acute Renal Failure,\" Annals of Internal Medicine, 105:303,1986 (letter) re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T13:39:49Z", null, 0, 0, "09000064805da238"], ["FDA-1977-N-0025-0050", "FDA", "FDA-1977-N-0025", "Reference 64: Sheiner, P. A. et al., \"Acute Renal Failure Associated with the Use of Ibuprofen in Two Liver Transplant Recipients on FK506,\" Transplantation, 57:1132-1133,1994 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T13:52:23Z", null, 0, 0, "09000064805da23e"], ["FDA-1977-N-0025-0084", "FDA", "FDA-1977-N-0025", "Reference 156: Habib, S. et al., \"A Study of the Comparative Effectiveness of Four Common Analgesics in the Control of Post-Surgical Dental Pain,\" Oral Surgery, Oral Medicine, and Oral Pathology, 70:559-563,1990 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T20:24:31Z", null, 0, 0, "09000064805da259"], ["FDA-1977-N-0025-0132", "FDA", "FDA-1977-N-0025", "Reference 127: Fitt, A., M. Dayan, and R. F. Gillie, \"Vortex Keratopathy Associated with Ibuprofen Therapy,\" Eye. 10:145-146, 1996 (letters) re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T18:12:02Z", null, 0, 0, "09000064805da27f"], ["FDA-1977-N-0025-0030", "FDA", "FDA-1977-N-0025", "Reference 69: Alam, I., L. D. Ferrell, and N. M. Bass, \"Vanishing Bile Duct Syndrome Temporally Associated with Ibuprofen Use,\" American Journal of Gastroenterology, 91:1626-1630, 1996 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:08:59Z", null, 0, 0, "09000064805da22a"], ["FDA-1977-N-0025-0025", "FDA", "FDA-1977-N-0025", "Reference 94: Treves, R. et al., \"Aseptic Meningitis and Acute Renal Failure Induced by Ibuprofen During the Treatment of Systemic Lupus Erythematosus,\" Revue de Rheumatisme, 50:75-76, 1983 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T15:16:31Z", null, 0, 0, "09000064805da225"], ["FDA-1977-N-0025-0074", "FDA", "FDA-1977-N-0025", "Reference 102: Mifsud, A. J., \"Drug-Related Recurrent Meningitis,\" Journal of Infection, 17:151- 153, 1988. re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T15:43:53Z", null, 0, 0, "09000064805da263"], ["FDA-1977-N-0025-0228", "FDA", "FDA-1977-N-0025", "Appendix A re: Comment from McNeil Consumer & Specialty Pharmaceuticals", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-11T13:17:26Z", null, 0, 0, "09000064805da2e3"], ["FDA-1977-N-0025-0151", "FDA", "FDA-1977-N-0025", "Reference 5: Minutes of the Seventeenth Meeting of the Arthritis Advisory Committee, OTC Vol. 03BTFM(I), Docket No. 77N-094I, Dockets Management Branch re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T13:02:29Z", null, 0, 0, "09000064805da296"], ["FDA-1977-N-0025-0140", "FDA", "FDA-1977-N-0025", "Reference 35: Walter, K., and C. Dilger, \"Ibuprofen in Human Milk,\" British Journal of Clinical Pharmacology. 44:211-212 1997 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T14:11:01Z", null, 0, 0, "09000064805da2a1"], ["FDA-1977-N-0025-0137", "FDA", "FDA-1977-N-0025", "Reference 38: Motrin (prescription) Label, in Physicians' Desk Reference. 54th ed. Directory Services edited by David W. Sifton, Medical Economics Company, Inc., Montvale, NJ, pp 1684- 1687, 2000 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T14:24:54Z", null, 0, 0, "09000064805da2a4"], ["FDA-1977-N-0025-0067", "FDA", "FDA-1977-N-0025", "Reference 43: Kaufman, D. W. et al., \"Nonsteroidal Anti-inflammatory Drug Use in Relation to Major Upper Gastrointestinal Bleeding,\" Clinical Pharmacology and Therapeutics. 53:485-494, 1993 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T14:44:07Z", null, 0, 0, "09000064805da24f"], ["FDA-1977-N-0025-0058", "FDA", "FDA-1977-N-0025", "Reference 50: Farquhar, W. B. et al., \"Effects of Acetaminophen and Ibuprofen on Renal Function in the Stressed Kidney,\" Journal of Applied Physiology, 86:598-604, 1999 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T13:21:59Z", null, 0, 0, "09000064805da246"], ["FDA-1977-N-0025-0045", "FDA", "FDA-1977-N-0025", "Reference 57: Wattad, A., et al., \"A Unique Complication of Nonsteroidal Anti-inflammatory Drug Use,\" Pediatrics. 93:693, 1993 (letter) re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T13:38:13Z", null, 0, 0, "09000064805da237"], ["FDA-1977-N-0025-0099", "FDA", "FDA-1977-N-0025", "Reference 118: Laing, V. B., E. F. Sherertz, and F. P. Flowers., \"Pemphigold-like Bullous Eruption Related to Ibuprofen,\" Journal of the American Academy of Dermatology, 19:91-94, 1988 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T17:46:51Z", null, 0, 0, "09000064805da275"], ["FDA-1977-N-0025-0096", "FDA", "FDA-1977-N-0025", "Reference 121: Pavithran, K., \"Exacerbation of Psoriasis by Ibuprofen,\" Indian Journal of Dermatology, Venereology, and Leprology. 53:372-373, 1987 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T17:57:20Z", null, 0, 0, "09000064805da279"], ["FDA-1977-N-0025-0131", "FDA", "FDA-1977-N-0025", "Reference 128: Ridder III, W. H., and A. Tomlinson, \"Effect of Ibuprofen on Contrast Sensitivity,\" Optometry and Vision Science, 69:652-655, 1992 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T18:16:27Z", null, 0, 0, "09000064805da280"], ["FDA-1977-N-0025-0122", "FDA", "FDA-1977-N-0025", "Reference 138: Cooper, S. A., \"Five Studies on Ibuprofen for Postsurgical Dental Pain (Study 5),\" American Journal of Medicine, 77:70-77, 1984 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T19:38:11Z", null, 0, 0, "09000064805da289"], ["FDA-1977-N-0025-0029", "FDA", "FDA-1977-N-0025", "Reference 68: Fukui, M. et al., \"A Case of Drug-Induced Hepatitis with Multinuclear Giant Hepatic Cells in Adult,\" Kanzo. 26:500-505, 1985 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:07:00Z", null, 0, 0, "09000064805da229"], ["FDA-1977-N-0025-0032", "FDA", "FDA-1977-N-0025", "Reference 71: Katz, L. M., and P. Y. Love, \"NSAIDs and the Liver,\" in Therapeutic Applications of NSAIDs (Chapter 12), edited by J. P. Famaey and H. E. Paulus, Marcel Dekker, Inc., New York, NY, pp. 247-263,1992 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:12:45Z", null, 0, 0, "09000064805da22c"], ["FDA-1977-N-0025-0051", "FDA", "FDA-1977-N-0025", "Reference 65: Rault, R. M., \"Case Report: Hyponatremia Associated with Nonsteroidal Anti-inflammatory Drugs,\" American Journal of the Medical Sciences, 305:318-320, 1993 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:00:27Z", null, 0, 0, "09000064805da23f"], ["FDA-1977-N-0025-0031", "FDA", "FDA-1977-N-0025", "Reference 70: Garcia-Rodriguez, L.A. et al., \"The Role of Non-Steroidal Anti-inflammatory Drugs in Acute Liver Injury,\" British Medical Journal, 305:865-868, 1992 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:10:39Z", null, 0, 0, "09000064805da22b"], ["FDA-1977-N-0025-0077", "FDA", "FDA-1977-N-0025", "Reference 99: Hanson, L., and H. J. Morgan, \"Ibuprofen-induced Aseptic Meningitis,\" Journal of Tennessee Medical Association, 87:58, 1994 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T15:38:15Z", null, 0, 0, "09000064805da260"], ["FDA-1977-N-0025-0072", "FDA", "FDA-1977-N-0025", "Reference 104: Chez, M. et al., \"Ibuprofen-lnduced Meningitis: Detection of Intrathecal IgG Synthesis and Immune Complexes,\" Neurology, 39:1578-1580, 1989 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T15:49:18Z", null, 0, 0, "09000064805da265"], ["FDA-1977-N-0025-0212", "FDA", "FDA-1977-N-0025", "Table of Contents re: Comment from McNeil Consumer & Specialty Pharmaceuticals", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-01-31T20:11:05Z", null, 0, 0, "09000064805da2eb"], ["FDA-1977-N-0025-0190", "FDA", "FDA-1977-N-0025", "Appendix I re: Comment from Wyeth Consumer Healthcare", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-04-05T19:48:47Z", null, 0, 0, "09000064805da2cd"], ["FDA-1977-N-0025-0177", "FDA", "FDA-1977-N-0025", "Background Material", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2018-01-02T19:25:09Z", null, 0, 0, "09000064805da2bf"], ["FDA-1977-N-0025-0037", "FDA", "FDA-1977-N-0025", "Reference 75: Wittkowsky, A. K., \"Thrombosis,\" Applied Therapeutics: The Clinical Use of Drugs, 6th ed., edited by Young, L. Y., and M. A. Koda-Kimble, Applied Therapeutics, Inc., Vancouver, WA, pp. 12-20-12-21, 1995 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:23:06Z", null, 0, 0, "09000064805da230"], ["FDA-1977-N-0025-0035", "FDA", "FDA-1977-N-0025", "Reference 77: Ayers, J. G., D. M. Flemming, and R. M. Whittington, \"Asthma Death Due to Ibuprofen,\" Lancet, 1:1082, 1987 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:27:22Z", null, 0, 0, "09000064805da232"], ["FDA-1977-N-0025-0011", "FDA", "FDA-1977-N-0025", "Reference 80: Jamil, A. S., and F. S. Majid, \"Life-Threatening Bronchial Asthma and Anti-inflammatory Drugs,\" The Journal of the Kuwaiti Medical Association, 22:165-167, 1988 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:33:42Z", null, 0, 0, "09000064805da217"], ["FDA-1977-N-0025-0015", "FDA", "FDA-1977-N-0025", "Reference 84: Harman Fridrich, H., G. A. Zach, and K. L. Fridrich, \"Aspirin-Intolerance Syndrome: Report of a Case,\" Oral Surgery, Oral Medicine, and Oral Pathology, 61:463-465, 1986 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:43:30Z", null, 0, 0, "09000064805da21b"], ["FDA-1977-N-0025-0082", "FDA", "FDA-1977-N-0025", "Reference 158: Milsom, I., and B. Andersch, \"Effect of Ibuprofen, Naproxen Sodium, and Paracetamol on Intrauterine Pressure and Menstrual Pain in Dysmenorrhea,\" British Journal of Obstetrics and Gynecology, 91:1129-1135, 1984 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T20:32:23Z", null, 0, 0, "09000064805da25b"], ["FDA-1977-N-0025-0017", "FDA", "FDA-1977-N-0025", "Reference 86: Katz, J. et al., \"Drug Allergy in Sjogren's Syndrome,\" Lancet. 337:239, 1991 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T14:48:19Z", null, 0, 0, "09000064805da21d"], ["FDA-1977-N-0025-0119", "FDA", "FDA-1977-N-0025", "Reference 144: Forbes, J. A. et al., \"Evaluation of Ketorolac, Ibuprofen, Acetaminophen, and an Acetaminophen-Codeine Combination in Post-Operative Oral Surgery Pain,\" Pharmacotherapy, 10 (Suppl. 6):94S-105S, 1990 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T19:52:52Z", null, 0, 0, "09000064805da28c"], ["FDA-1977-N-0025-0090", "FDA", "FDA-1977-N-0025", "Reference 149: Mehlisch, D. R. et al., \"Multi-Center Clinical Trial of Ibuprofen and Acetaminophen in the Treatment of Postoperative Dental Pain,\" Journal of American Dental Association,121:257-263, 1990 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T20:08:20Z", null, 0, 0, "09000064805da253"], ["FDA-1977-N-0025-0196", "FDA", "FDA-1977-N-0025", "Request for Extension from Wyeth Consumer Healthcare", "Other", "Request for Extension", "2018-01-02T05:00:00Z", 2018, 1, "2018-01-02T05:00:00Z", "2002-11-20T04:59:59Z", "2019-02-01T16:52:28Z", null, 0, 0, "09000064805da2c7"], ["FDA-1977-N-0025-0206", "FDA", "FDA-1977-N-0025", "Reference List re: Comment from McNeil Consumer & Specialty Pharmaceuticals", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-01-31T20:28:50Z", null, 0, 0, "09000064805da2e5"], ["FDA-1977-N-0025-0144", "FDA", "FDA-1977-N-0025", "Background Material-CP13", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2018-01-02T19:17:49Z", null, 0, 0, "09000064805da29d"], ["FDA-1977-N-0025-0170", "FDA", "FDA-1977-N-0025", "Reference 18: Cox, S. R., \"Effect of Route of Administration on the Chiral Inversion of R(-)-Ibuprofen\" (abstract). Clinical Pharmacology and Therapeutics. 43:146, 1988 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T13:29:56Z", null, 0, 0, "09000064805da2ad"], ["FDA-1977-N-0025-0136", "FDA", "FDA-1977-N-0025", "Reference 40: Moore, N. et al., \"The PAIN Study: Paracetamol, Aspirin, and Ibuprofen, New Tolerability Study. A Large-Scale, Randomized Clinical Trial Comparing the Tolerability of Aspirin, Ibuprofen and Paracetamol for Short-Term Analgesia,\" Clinical Drug Investigations. 18:89-98, 1999 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-06T14:30:42Z", null, 0, 0, "09000064805da2a5"], ["FDA-1977-N-0025-0061", "FDA", "FDA-1977-N-0025", "Reference 53: Furey, S. A., R. Vargas, and F. G. McMahan, \"Renovascular Effects of Nonprescription Ibuprofen in Elderly Hypertensive Patients with Mild Renal Impairment,\" Pharmacotherapy, 13:143-148, 1993 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T13:29:28Z", null, 0, 0, "09000064805da249"], ["FDA-1977-N-0025-0086", "FDA", "FDA-1977-N-0025", "Reference 154: Schachtel, B. P., W. R. Thoden, and R. I. Baybutt, \"Ibuprofen and Acetaminophen in the Relief of Postpartum Episiotomy Pain,\" Journal of Clinical Pharmacology, 29:550-553, 1989 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T20:20:28Z", null, 0, 0, "09000064805da257"], ["FDA-1977-N-0025-0201", "FDA", "FDA-1977-N-0025", "Table of Contents re: Comment from McNeil Consumer & Specialty Pharmaceuticals", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-21T12:56:50Z", null, 0, 0, "09000064805da2dd"], ["FDA-1977-N-0025-0223", "FDA", "FDA-1977-N-0025", "Tab 5 re: Comment from Albemarle Corporation", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-22T14:20:49Z", null, 0, 0, "09000064805da2f6"], ["FDA-1977-N-0025-0108", "FDA", "FDA-1977-N-0025", "Reference 109: Hoppmann, R. A., J. G. Peden, and S. K. Ober, \"Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs,\" Archives of Internal Medicine, 151:1309-1313, 1991 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T17:23:07Z", null, 0, 0, "09000064805da26b"], ["FDA-1977-N-0025-0068", "FDA", "FDA-1977-N-0025", "Reference 146: Forbes, J. A. et al., \"Analgesic Efficacy of Bromfenac, Ibuprofen, and Aspirin in Postoperative Oral Surgery Pain,\" Clinical Pharmacology, 51:343-352, 1992 re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-07T20:00:57Z", null, 0, 0, "09000064805da250"], ["FDA-1977-N-0025-0150", "FDA", "FDA-1977-N-0025", "Reference 6: Summary Basis of Approval for New Drug Application for Ibuprofen (200 mg), OTC Vol. 03BTFM (1), Docket No. 77N-0941, Dockets Management Branch re: Background Material Public Administrative File OTC Volume 03BTFM (1) (Vol. 1 of 3)", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-04T18:58:15Z", null, 0, 0, "09000064805da297"], ["FDA-1977-N-0025-0208", "FDA", "FDA-1977-N-0025", "3 NDAC Issues Raised re: Comment from McNeil Consumer & Specialty Pharmaceuticals", "Supporting & Related Material", "Background Material", "2018-01-02T05:00:00Z", 2018, 1, null, null, "2019-02-01T16:22:55Z", null, 0, 0, "09000064805da2e7"]], "truncated": false, "filtered_table_rows_count": 215, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"docket_id\" = :p1 and \"posted_year\" = :p2 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "FDA-1977-N-0025", "p2": "2018"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018", "results": [{"value": "FDA", "label": "FDA", "count": 215, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-1977-N-0025&posted_year=2018", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 210, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Other", "label": "Other", "count": 4, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&document_type=Other", "selected": false}, {"value": "Proposed Rule", "label": "Proposed Rule", "count": 1, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&document_type=Proposed+Rule", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018", "results": [{"value": 2018, "label": 2018, "count": 215, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&_facet=comment_start_date"}, {"name": "posted_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&_facet_date=last_modified"}], "next": "2018-01-02T05~3A00~3A00Z,FDA-1977-N-0025-0208", "next_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1977-N-0025&posted_year=2018&_next=2018-01-02T05~3A00~3A00Z%2CFDA-1977-N-0025-0208&_sort_desc=posted_date", "private": false, "allow_execute_sql": true, "query_ms": 1101.8924959935248, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}